JLJie Liu

Jie Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jie Liu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Changsheng Xu

    Fujian Hypertension Research Institute The First Affiliated Hospital of Fujian Medical University, Fujian 350005, China

    1 shared publication
  • Chengfang Lv

    Department of Hematology, South University of Science and Technology Hospital, Shenzhen, China

    1 shared publication
  • Dajun Chai

    Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province

    1 shared publication
  • Hong Xie

    Institute of Photonic Chips, School of Artificial Intelligence Science and Technology, University of Shanghai for Science and Technology, Shanghai, China

    1 shared publication
  • Hongbin Meng

    Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, China; and

    1 shared publication
  • Hongjuan Yu

    Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication

Latest Publications

  • Open Access

    miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT

    by Yueyue Fu, Limin Li, Jinxiao Hou, Huibo Li, Chengfang Lv, Hongjuan Yu, Xiaoqian Zhang, Mengyuan Xu, Mingwen Zhang, Hongbin Meng, et al.

    Acute promyelocytic leukemia (APL) patients with progressive leukocytosis are more likely to have various complications and poor outcomes. However, the regulatory roles of microRNAs in the leukocytosis of APL have not been clarified. Our study aims to evaluate the effects of miRNAs on leukocytosis during induction therapy of APL patients and explore its potential mechanisms. During induction treatment, patients with white blood cell count higher than 10×109/L were divided into leukocytosis group and others were nonleukocytosis group. Using microarray assays, we found that miR-139-5p was significantly downregulated in the leukocytosis group. Elevated expression of miR-139-5p inhibited the proliferation of NB4 cells by arresting the cell cycle and inducing apoptosis. We further identified that MNT was a target of miR-139-5p. miR-139-5p significantly inhibited the proliferation, invasion, and migration function of NB4 cells through targeting MNT. Strategies for regulating miR-139-5p or MNT expression might provide new therapeutic approaches for progressive leukocytosis in APL.


  • Open Access

    Retinoid X receptor agonists attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes through LKB1-dependent anti-fibrosis effects

    by Dajun Chai, Xiaoyan Lin, Qiaowen Zheng, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, Jinzhang Zeng

    Diabetic cardiac fibrosis increases ventricular stiffness and facilitates the occurrence of diastolic dysfunction. Retinoid X receptor (RXR) plays an important role in cardiac development and has been implicated in cardiovascular diseases. In this study, we investigated the effects of RXR agonist treatment on streptozotocin (STZ)-induced diabetic cardiomyopathy (DCM) and the underlying mechanism. Sprague-Dawley rats induced by STZ injection were treated with either RXR agonist bexarotene or vehicle alone. Echocardiography was performed to determine cardiac structure and function. Cardiac fibroblasts (CFs) were treated with high glucose with or without the indicated concentration of bexarotene or the RXR ligand 9-cis-retinoic acid (9-cis-RA). The protein abundance levels were measured along with collagen, body weight, blood biochemical indexes and TGF-β levels. The effects of RXRα downregulation by RXRα small interfering RNA were examined. The results showed that bexarotene treatment resulted in amelioration of left ventricular dysfunction by inhibiting cardiomyocyte apoptosis and myocardial fibrosis. Immunoblot with heart tissue homogenates from diabetic rats revealed that bexarotene activated LKB1 signaling and inhibited p70S6K. The increased collagen levels in the heart tissues of DCM rats were reduced by bexarotene treatment. Treatment of CFs with high glucose resulted in significantly reduced LKB1 activity and increased p70S6K activity. RXRα mediated the antagonism of 9-cis-RA on high glucose-induced LKB1/p70S6K activation changes in vitro. Our findings suggest that RXR agonist ameliorates STZ-induced DCM by inhibiting myocardial fibrosis via modulation of the LKB1/p70S6K signaling pathway. RXR agonists may serve as novel therapeutic agents for the treatment of DCM.